Slide 1: Q2 2024 Financial Results & Business Update
1 Q2 2024 Financial Results & Business Update Nasdaq: OABI August 8, 2024
Slide 2: Disclaimer
2 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected operating expense and cash
Slide 3: Introduction
Omni Introduction : Matt Foehr
Slide 4: Positioning the Business for Growth and Success
4 Positioning the Business for Growth and Success Q2 2024 Adding new partners to a growing and diverse base, as programs advance to and through the clinic Driving growth in the business with strong execution, an efficient operating structure and a highly scalable model Gaining further visibility for
Slide 5: Active Partners
5 Active Partners 83 ACTIVE PARTNERS AS OF 6/30/2024 Number of Active Partners 80 60 • 2 new platform license agreements were signed in the second quarter ‒ New platform license agreements with DAAN Bio and Topaz Therapeutics 40 (focused on radioconjugates) 20 0 Represents the unique number of partn
Slide 6: Growth and Diversity of Our Partnership Base
6 Growth and Diversity of Our Partnership Base 30% GROWTH IN ACTIVE PARTNERS OVER THE LAST 24 MONTHS Number of Active Partners 83 Academic partner licenses are designed for revenue sharing, with discovery 74 technology platform access and an understanding that programs can be efficiently spun out in
Slide 7: Geographic Distribution of Partners
7 Geographic Distribution of Partners AS OF 6/30/2024 Asia 20% North America 58% Europe 22% n = 83 Our diversified set of partners are distributed globally Based on geographic location of partner headquarters
Slide 8: Active Programs
8 Active Programs GROWTH AND PROGRESSION CONTINUES WITH 333 ACTIVE PROGRAMS Number of 333 Active Programs Active Programs as of 6/30/2024 Phase 3: 2 300 Phase 2: 2 Registration: 1 • Number of Active Programs increased Phase 1: 24 Approved: 3 to 333, net of attrition Preclinical: 18 200 • During the
Slide 9: Preclinical and Later-Stage Programs Continued to Grow
9 Preclinical and Later-Stage Programs Continued to Grow 39% GROWTH OVER THE LAST 24 MONTHS As of 6/30/2024 Approved: 3 As of 6/30/2023 Registration: 1 Phase 3: 2 As of 6/30/2022 Registration: 1 Approved: 3 Phase 2: 2 Registration: 1 Phase 3: 1 Preclinical: 18 Approved: 2 Phase 3: 2 Phase 2: 2 Precl
Slide 10: Active Clinical Programs and Approved Products
10 Active Clinical Programs and Approved Products Number of Active Clinical Programs and Approved Products • 32 active clinical programs and approved products as of 6/30/2024(1) 30 • TEVA’s OmniChicken-derived TEV-56278 (Anti-PD1-IL-2 ATTENUKINE ) 20 entered Phase 1 clinical trial(2) in Q2 10 • Incl
Slide 11: OmniAb Antibodies are Adaptable to a Wide Variety of Formats
11 OmniAb Antibodies are Adaptable to a Wide Variety of Formats Monospecific Multispecific Conjugated IgG Duobody® Fab-VHH ADAPTIR IgG-scFv IgG-Anticalin® ADC (IgG4 exchange) (Knob-in-hole) scFv-Fc-scFv Fab-Fc/ ATTENUKINE HexaBody® Common LC ECD-Fc-Fab TRAAC scFv-Fc-scFv (Knob-in-hole) Continuing to
Slide 12: Select Partner Updates
12 Select Partner Updates RECENT DEVELOPMENTS CONTINUE TO DEMONSTRATE PARTNER PROGRESS Acasunlimab Sugemalimab CSX-1004 TEV-56278 Anti-PD-L1 x 4-1BB Anti-PD-L1 Anti-Fentanyl Anti-PD1-IL-2 Genmab announced initial data from the CStone announced that the European Cessation announced the presentation T
Slide 13: Select Potential Upcoming Partner Events
13 Select Potential Upcoming Partner Events POTENTIAL PARTNER PROGRESSION EVENTS IN THE COMING 18 MONTHS 2H 2024 2025 Multiple Partners: New clinical starts IMVT-1402: Potential registration trial for myasthenia gravis initiation (prior to March 31, 2025) Acasunlimab: Initiation of global Phase 3 tr
Slide 14: Licenses for Current Active Programs Have Significant Future Milestone Potential
Licenses for Current Active Programs Have Significant 14 Future Milestone Potential Potential Milestones for Active Antibody Programs >$3 billion Potential Milestones for Preclinical to Registration Programs Potential Milestones for Active Small Molecule >$550 million Ion Channel Programs ̴ $700 mil
Slide 15: Financial Updates
15 Financial Updates Kurt Gustafson
Slide 16: Q2 2024 vs. Q2 2023 Financial Results
16 Q2 2024 vs. Q2 2023 Financial Results (Millions, except per share data) Q2 2024 Q2 2023 Variance License and milestone revenue $ 3.1 $ 4.3 ($ 1.2) Service revenue 4.2 2.5 1.7 Royalty revenue 0.3 0.2 0.2 Total revenues 7.6 6.9 0.7 Research & development 13.9 14.1 (0.2) We now expect total operatin
Slide 17: Balance Sheet
17 Balance Sheet (Millions) June 30, December 31, 2024 2023 ASSETS We expect cash use in 2024 to be relatively Current assets: similar to the cash use in 2023, excluding the Cash & investments $ 57.2 $ 87.0 $35M TECVAYLI® milestone that was received Accounts receivable, net 6.9 3.8 in Q1 2023 Other
Slide 18: Q&A
Omni Q&A
Slide 19: Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline
Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline AS OF 6/30/2024 19 Partner Program Source Animal Therapy Area Target Phase 1 Phase 2 Phase 3 Registration Approved Zimberelimab OmniRat Oncology PD-1 Sugemalimab OmniRat Oncology PD-L1 Teclistamab OmniRat Oncology BCMA x CD3 Batoc
Slide 20: Omni >
Omni >